Ascendis Pharma A/S Announces Entire 12 months 2020 Fiscal Success and Business enterprise Update Conference Phone on March 10

Pamela G. Knowles

COPENHAGEN, Denmark, March 04, 2021 (Globe NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical enterprise that utilizes its innovative TransCon™ technologies to develop products candidates that deal with unmet clinical requirements, nowadays introduced that the company will hold a convention simply call and live webcast on Wednesday, March 10, 2021 at 4:30 p.m. Jap Time (ET) to assessment its 2020 economic results and supply a business enterprise update.

Convention Contact Aspects


Wednesday, March 10, 2021


4:30 p.m. ET/1:30 p.m. Pacific Time

Dial In (U.S.)


Dial In (Global)


Accessibility Code


A are living webcast of the meeting contact will be out there on the Investors and News part of the Ascendis Pharma web page at A webcast replay will be out there on this internet site shortly soon after summary of the function for 30 times.

About Ascendis Pharma A/S

Ascendis Pharma is making use of its innovative TransCon technologies to create a main, totally built-in biopharmaceutical company concentrated on producing a meaningful variance in patients’ lives. Guided by its main values of clients, science and enthusiasm, the corporation utilizes its TransCon technologies to build new and perhaps most effective-in-class therapies.

Ascendis Pharma at the moment has a pipeline of 3 independent endocrinology uncommon disorder products candidates and one oncology item applicant in scientific advancement. The firm continues to extend into extra therapeutic parts to address unmet patient requirements.

Ascendis is headquartered in Copenhagen, Denmark, with added offices in Heidelberg and Berlin, Germany, Palo Alto and Redwood Town, California, and Princeton, New Jersey.

Please visit (for world wide data) or (for U.S. details.)

Ahead-Looking Statements

This press release includes ahead-searching statements that require considerable hazards and uncertainties. All statements, other than statements of historical points, incorporated in this push launch concerning Ascendis’ potential functions, strategies and aims of management are ahead-seeking statements. Examples of this kind of statements involve, but are not restricted to, statements relating to (i) Ascendis’ capability to utilize its TransCon systems to develop a top, fully built-in biopharmaceutical company, (ii) Ascendis’ solution pipeline and growth into supplemental therapeutic regions and (iii) Ascendis’ anticipations regarding its capability to use its TransCon systems to generate new and perhaps most effective-in-course therapies. Ascendis may well not truly realize the programs, carry out the intentions or meet the anticipations or projections disclosed in the ahead-wanting statements and you must not place undue reliance on these forward-wanting statements. Real effects or functions could differ materially from the programs, intentions, expectations and projections disclosed in the ahead-hunting statements. Many essential components could bring about true success or functions to differ materially from the ahead-searching statements that Ascendis makes, such as the pursuing: unexpected protection or efficacy benefits in its oncology packages, TransCon hGH, TransCon PTH and TransCon CNP or other enhancement packages unforeseen expenses connected to the growth and prospective commercialization of its oncology programs, TransCon hGH, TransCon PTH and TransCon CNP or other improvement plans, offering, typical and administrative bills, other research and growth costs and Ascendis’ enterprise usually delays in the progress of its oncology packages, TransCon hGH, TransCon PTH and TransCon CNP or other progress packages similar to producing, regulatory requirements, speed of affected person recruitment or other unexpected delays dependence on 3rd bash producers to source review drug for prepared clinical studies Ascendis’ skill to get added funding, if required, to guidance its business things to do and the results on its small business from the around the world COVID-19 pandemic. For a additional description of the challenges and uncertainties that could cause precise outcomes to vary from all those expressed in these ahead-seeking statements, as very well as dangers relating to Ascendis’ business enterprise in general, see Ascendis’ prospectus nutritional supplement submitted on July 9, 2020 and Ascendis’ latest and long term reports filed with, or submitted to, the U.S. Securities and Exchange Fee (SEC), such as its Yearly Report on Sort 20-F submitted with the SEC on April 3, 2020. Forward-on the lookout statements do not reflect the opportunity effects of any upcoming in-licensing, collaborations, acquisitions, mergers, tendencies, joint ventures, or investments that Ascendis could enter into or make. Ascendis does not presume any obligation to update any forward-seeking statements, except as needed by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma brand, the business logo and TransCon are emblems owned by the Ascendis Pharma Group. © March 2021 Ascendis Pharma A/S.

Next Post

New Mexico teen catches potentially file breaking fish, releases it before receiving formal bodyweight

Age doesn’t beat encounter. A teen in New Mexico is getting credited with catching a 55-pound blue catfish. While the fish’s bodyweight is extraordinary, it hasn’t gained an formal rating simply because of the way the excess weight was recorded. The potentially record-breaking fish was caught by 13-year-aged Alonso Ordaz, […]

Subscribe US Now